6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial

The Lancet

Volumn 391, Issue 10127, 2018, Pages 1274-1284

  Hahn, Joo Yong ^a,o   Song, Young Bin ^a,o   Oh, Ju Hyeon ^a   Cho, Deok Kyu ^b,o   Lee, Jin Bae ^c,o   Doh, Joon Hyung ^d,o   Kim, Sang Hyun ^e,o   Jeong, Jin Ok ^f,o   Bae, Jang Ho ^g,o   Kim, Byung Ok ^h,o   Cho, Jang Hyun ^i,o   Suh, Il Woo ^j,o   Kim, Doo il ^d,o   Park, Hoon Ki ^k,o   Park, Jong Seon ^l,o   Choi, Woong Gil ^m,o   Lee, Wang Soo ^n,o   Kim, Jihoon ^a   Choi, Ki Hong ^a   Park, Taek Kyu ^a,o   Lee, Joo Myung ^a,o   Yang, Jeong Hoon ^a,o   Choi, Jin Ho ^a,o   Choi, Seung Hyuk ^a,o   Gwon, Hyeon Cheol ^a,o   Lee, Jong Young ^o   Park, Hun Sik ^o   Hwang, Jin Yong ^o   Hur, Seung Ho ^o   Rha, Seung Woon ^o   Cho, Sang Cheol ^o   Kang, Won You ^o   Lim, Seong Hoon ^o   Kim, Moo Hyun ^o   Cha, Kwang Soo ^o   Choi, Rak Kyung ^o   Chae, In Ho ^o   Oh0h, Ju Hyeon ^o   Jang, Woo Jin ^o   Park, Yong Hawn ^o   Chun, Woo Jung ^o   Choi, Jae Woong ^o   Jeong, Myung Ho ^o   Kang, Seung Ho ^o   Ahn, Kyung Ju ^o   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seonam University of Medicine Myongji Hospital   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Inje University   (South Korea)

^e Seoul National University Boramae Hospital   (South Korea)

^f Chungnam National University College of Medicine   (South Korea)

^g Konyang University College of Medicine   (South Korea)

^h Inje University College of Medicine   (South Korea)

ⁱ St Carollo General Hospital   (South Korea)

^j Sam Medical Center   (South Korea)

^k Seoul Veterans Hospital   (South Korea)

^l Young Nam University Hospital   (South Korea)

^m Konkuk University Hospital   (South Korea)

ⁿ Chung Ang University College of Medicine   (South Korea)

^o Chung Ang University Hospital ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DUAL ANTIPLATELET THERAPY; FEMALE; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NON-INFERIORITY TRIAL; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; TICLOPIDINE; TREATMENT OUTCOME;

EID: 85043381536     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30493-8     Document Type: Article

References (31)

1. Kukreja, N, Onuma, Y, Garcia-Garcia, HM, et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2 (2009), 534–541.
2. Loh, JP, Pendyala, LK, Kitabata, H, et al. Comparison of outcomes after percutaneous coronary intervention among different coronary subsets (stable and unstable angina pectoris and ST-segment and non-ST-segment myocardial infarction). Am J Cardiol 113 (2014), 1794–1801.
3. Levine, GN, Bates, ER, Bittl, JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
4. Valgimigli, M, Bueno, H, Byrne, RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39 (2018), 213–260.
5. Mehta, SR, Yusuf, S, Peters, RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
6. Sabate, M, Raber, L, Heg, D, et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv 7 (2014), 55–63.
7. Palmerini, T, Benedetto, U, Biondi-Zoccai, G, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 65 (2015), 2496–2507.
8. Investigators, TC, Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001), 1385–1390.
9. Cannon, CP, Braunwald, E, McCabe, CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
10. Yang, JH, Hahn, JY, Song, YB, et al. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. BMJ, 349, 2014, g6650.
11. Varenhorst, C, Jensevik, K, Jernberg, T, et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J 35 (2014), 969–978.
12. Costa, F, Vranckx, P, Leonardi, S, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. Eur Heart J 36 (2015), 1242–1251.
13. Song, PS, Hahn, JY, Kim, DI, et al. Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome. Eur J Intern Med 26 (2015), 521–527.
14. Palmerini, T, Della Riva, D, Benedetto, U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 38 (2017), 1034–1043.
15. Lee, JM, Cho, DK, Hahn, JY, et al. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial. Am Heart J 182 (2016), 1–8.
16. Cutlip, DE, Windecker, S, Mehran, R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
17. Mehran, R, Rao, SV, Bhatt, DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
18. Gwon, HC, Hahn, JY, Park, KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
19. Serruys, PW, Morice, MC, Kappetein, AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009), 961–972.
20. Park, SJ, Kim, YH, Park, DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 364 (2011), 1718–1727.
21. Mauri, L, Kereiakes, DJ, Yeh, RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
22. Giustino, G, Baber, U, Sartori, S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 65 (2015), 1298–1310.
23. Bonaca, MP, Bhatt, DL, Cohen, M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
24. Urban, P, Meredith, IT, Abizaid, A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 373 (2015), 2038–2047.
25. Natsuaki, M, Morimoto, T, Yamamoto, E, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 31 (2016), 196–209.
26. Varenne, O, Cook, S, Sideris, G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet 391 (2018), 41–50.
27. Stone, GW, Maehara, A, Lansky, AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364 (2011), 226–235.
28. Hong, MK, Mintz, GS, Lee, CW, et al. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation 110 (2004), 928–933.
29. Kim, C, Shin, DH, Ahn, CM, et al. The use pattern and clinical impact of new antiplatelet agents including prasugrel and ticagrelor on 30-day outcomes after acute myocardial infarction in Korea: Korean health insurance review and assessment data. Korean Circ J 47 (2017), 888–897.
30. Kedhi, E, on behalf of the DAPT STEMI Investigators and Steering Committee. DAPT STEMI: a randomized trial of 6-month vs 12-month DAPT After DES implantation in STEMI. TCTMD. https://www.tctmd.com/slide/dapt-stemi-randomized-trial-6-month-vs-12-month-dapt-after-des-implantation-stemi, Nov 1, 2017 (accessed Dec 5, 2017).
31. Suryapranata, H, on behalf of the REDUCE trial investigators. REDUCE: a randomized trial of 3-month vs 12-month DAPT after implantation of a bioabsorbable polymer-based metallic DES with a luminal CD34+ antibody coating in patients with ACS. TCTMD. https://www.tctmd.com/slide/reduce-randomized-trial-3-month-vs-12-month-dapt-after-implantation-bioabsorbable-polymer, Nov 1, 2017 (accessed Dec 5, 2017).